Krystal Biotech, Inc.
KRYS
Peringkat dalam Saham
#2151
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Harga Saham
$324.96
Kapitalisasi Pasar
$9.62B
Perubahan (1 hari)
1.47%
Perubahan (1 tahun)
65.83%
Negara
US
Perdagangan Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
Laba untuk Krystal Biotech, Inc. (KRYS)
Laba pada Jun 2026 TTM: $226.62M
Menurut laporan keuangan terbaru dari Krystal Biotech, Inc., laba saat ini perusahaan adalah $226.62M. Pada tahun 2023, perusahaan memperoleh laba sebesar $12.90M, peningkatan dibandingkan laba tahun 2022 sebesar $-139.98M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Krystal Biotech, Inc. dari 2016 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $226.62M | 137.66% |
| 2024 | $95.36M | 639.37% |
| 2023 | $12.90M | -109.21% |
| 2022 | $-139.98M | 101.20% |
| 2021 | $-69.57M | 116.28% |
| 2020 | $-32.17M | 68.52% |
| 2019 | $-19.09M | 75.30% |
| 2018 | $-10.89M | 37.49% |
| 2017 | $-7.92M | 588.70% |
| 2016 | $-1.15M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | 2,227.64% |
US
|
|
| $-3.09B | -1,462.19% |
US
|
|
| $-4.02B | -1,872.22% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 760.76% |
NL
|
